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Variations in genes associated with cholesterol homeostasis have been reported to modify the
risk of developing Alzheimer disease (AD). To date there have been few investigations into
variations in genes directly involved in cholesterol biosynthesis and AD. We investigated the
influence of the -911C>A polymorphism (rs3761740) in the hydroxy-methyl-glutaryl CoA
reductase (HMGCR) gene promoter on basal and regulated transcription, plasma cholesterol
levels and the association with AD. Under in vitro conditions the A allele was found to be
significantly more responsive to SREBP-2 mediated regulation than the C allele. In an age
and sex matched case-control study, the genotype distribution and allele frequency of this
polymorphism were not associated with AD (OR=1.03; 95% CI=0.72-1.48). However, we did
find evidence supporting an interaction between the HMGCR A allele, the APOE E4 allele
and an altered risk of AD (OR=2.41; 95% CI=0.93-6.22).

Keywords: Alzheimer disease, single nucleotide polymorphism, HMGCR, promoter activity,
genetic association, cholesterol.
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Introduction

Alzheimer disease (AD) is the most common form of dementia. It is a neurodegenerative
disease defined histologically by the presence of extracellular neuritic plaques, neuronal loss
and intracellular neurofibrillary tangles in the brain. Mutations in three genes – amyloid
precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) – are known to cause
autosomal dominant early-onset AD. However, these mutations account for just a few percent
of all AD cases (Goate et al., 1991; Rogaev et al., 1995; Sherrington et al., 1995). While the
underlying cause of late-onset AD (LOAD) remains unknown a number of genetic risk factors
have been suggested (see (Tanzi and Bertram, 2005) for a review). The ε4 allele of
apolipoprotein E (APOE) has been shown to be a strong independent risk factor in the
development of LOAD, and is the only confirmed genetic risk factor for LOAD (Corder et al.,
1995; Corder et al., 1998; Poirier et al., 1993; Strittmatter et al., 1993). APOE is a major lipid
transport molecule in the central nervous system. Additionally, APOE acts as a scavenger of
soluble amyloid and has been hypothesized to play a role in amyloid plaque metabolism and
clearance (Beffert and Poirier, 1996; Deane et al., 2008). Very recent genome wide
association studies have provided compelling evidence that genetic variations in the
apolipoprotein J gene (also known as clusterin, CLU) are associated with the risk of
developing Alzheimer’s disease (Harold et al., 2009; Lambert et al., 2009; van Es and van den
Berg, 2009)

While all nucleated cells are capable of synthesizing cholesterol, the majority of cells meet
their cholesterol requirements via lipoprotein mediated uptake of cholesterol. A notable
exception to this is the brain, which synthesises all of the cholesterol it requires in situ, despite
accounting for more than one quarter of the body’s cholesterol mass. The importance of
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cholesterol for brain function is underscored by the severity of the clinical picture in inherited
disorders of cholesterol biosynthesis (see (Hennekam, 2005) for a review). Over the last
decade a number of studies have indicated that cholesterol plays a role in AD (see (Hartmann
et al., 2007) for a recent review). However, the mechanistic connection(s) between cholesterol
and the disease process remain obscure. While cholesterol has been found to influence
virtually all of the biochemical processes underlying AD in vitro, epidemiological studies
have shown that elevated midlife serum cholesterol is associated with an increased risk of AD
in later life (Kivipelto et al., 2001; Solomon et al., 2007; Stewart et al., 2007).

Numerous studies have investigated the relationship between variants of genes involved in the
processes underpinning brain cholesterol homeostasis and AD (Hartmann et al, 2007).
Variations in CYP46A1, which encodes cholesterol 24-hydroxylase, a key player in brain
cholesterol homeostasis, have been extensively investigated. Intronic polymorphisms in
CYP46A1 have been suggested to affect the load of both β-amyloid and phosphorylated tau
protein in the brains of AD patients (Johansson et al., 2004; Papassotiropoulos et al., 2003).
However, these association studies have shown inconsistent results concerning variations in
the CYP46A1 gene and the risk of AD (Desai et al., 2002; Helisalmi et al., 2006; Ingelsson et
al., 2004; Papassotiropoulos et al., 2003). In addition a meta-analysis of the available data
does not support a link between genetic variations in CYP46A1 and the risk of AD (Llorca et
al., 2008).

The availability of the statin class of cholesterol lowering agents has provided a facile means
to investigate the influence of cholesterol on the risk of developing AD and some, but not all,
studies have shown a protective effect of statins (Jick et al., 2000; Rea et al., 2005; Wolozin et
al., 2000; Zandi et al., 2005). Statins competitively inhibit the rate-limiting enzymatic step in
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cholesterol synthesis, hydroxy-methyl-glutaryl-coenzyme A reductase (HMGCR). Genetic
variations in the HMGCR gene have been suggested to modulate the cholesterol lowering
response to treatment with statins (Chasman et al., 2004).

Recently a single nucleotide polymorphism (SNP) in the promoter of HMGCR was reported
as a risk factor for AD (Porcellini et al., 2007). As a continuation of our investigations into the
molecular mechanisms underlying cholesterol homeostasis we considered it of interest to test
the hypothesis that this polymorphism [rs3761740] influences the activity of the HMGCR
promoter. Our finding of a strong effect on gene activity prompted us to evaluate the
association of this SNP with the risk of AD in a Swedish sample.
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Results

The HMGCR rs3761740 polymorphism is associated with an increased sensitivity to
SREBP

Careful inspection of the HMGCR promoter sequence revealed that the rs3761740
polymorphism was close to a potential SREBP binding site. To determine the effect of this
polymorphism on basal and SREBP-2 stimulated promoter activity, we transiently transfected
HEK293 cells with pGL3-HMG-A or pGL3-HMG-C. Basal activity of the pGL3-HMG-A
was significantly lower (P < 0.001) than that of pGL3-HMG-C (see Figure 2a). Subsequent
co-transfection with a plasmid expressing the active nuclear form of SREBP-2 resulted in a
significantly greater activation (P < 0.001) of pGL3-HMG-A compared to pGL3-HMG-C.
(Figure 2b). This corresponds to a four-fold induction of promoter activity over basal, in the
presence of the A allele and SREBP-2.

The HMGCR rs3761740 polymorphism is not associated with Alzheimer disease in
Swedish Cases
Previous studies have reported an association of the rs3761740 polymorphism with AD in an
Italian population (Porcellini et al., 2007). In light of our in vitro data we considered it
important to verify this data in a well defined, independent Swedish population. No
discordance could be detected for samples analysed twice and the success rate of genotyping
was ~99%. Neither the case or control sample set diverged from HWE (p=0.80 and p=0.98,
respectively). The frequencies of the C allele for the controls and AD cases were 88.9% and
89.2%, respectively (for genotype frequencies see Table 1), which is consistent with the
previous results from Porcellini et al (Porcellini et al., 2007). Unsurprisingly, the ε4 allele of
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APOE was present in 61% of the cases and 26% of the controls and the OR for AD for those
with the ε4 allele was 5.3, adjusted for cholesterol levels.

Mean cholesterol levels were significantly lower in patients than in controls (5.62±1.15 mM
vs. 5.90±1.08 mM, P = 0.002). When combining AD cases and controls, and adjusting for
age, gender and disease status, carriers of the APOE ε4 allele had significantly higher
cholesterol levels than ε4 negative individuals (5.97 ± 1.15 mM vs. 5.69 ± 1.09 mM,
F(1,604)=11.18, p<0.001). No difference was detected in cholesterol levels between A
carriers and non-A carriers of the HMGCR rs3761740 polymorophism (F91,601)=0.09, p=
0.76). Analysis of the total case-control series did not reveal a significant association between
presence of an A allele (i.e. AA+AC), compared with homozygosity for the C allele, and risk
for AD (unadjusted OR=1.03; 95% CI = 0.72-1.48; P = 0.86). However, we did notice a
tendency towards an interaction between the APOE ε4 and HMGCR -911A alleles in relation
to AD (OR=2.41, CI = 0.93-6.22, P=0.07). To clarify their relation the two variables were
combined in a categorical variable, based on cross tabulation, and introduced in a logistic
regression model (see Table 2) Compared with subjects who carry neither APOE ε4 nor the
HMGCR -911A allele, the OR for AD was 4.6 for subjects who carry the APOE ε4 alone, and
it was not increased for subjects who carry the HMGCR -911A allele alone. However, when
these two genes were present simultaneously, the OR increased to 6.2, approximately 36%
higher than that of carriers of the APOE ε4 alone.
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Discussion

There is strong evidence of an important role for cholesterol in the development of AD (Reid
et al., 2007). De novo synthesis of all isoprenoids, including cholesterol, is dependent on the
activity of HMGCR. In the present work we explored the influence of a promoter
polymorphism on the transcriptional activity of the HMGCR gene, on plasma cholesterol
levels and on the risk of AD in case and control from Sweden.

Using transient transfection assays with reporter gene constructs of the HMGCR promoter
representing either the C or A allele, we found a significant effect of the polymorphism on
both basal activity and response to SREBP-2. SREBP-2 is considered to be the global
regulator of cholesterol synthesis (Horton et al., 2003) and is known to increase HMGCR
transcripition (Sakakura et al., 2001). Our results are in contrast to a previous study where no
difference between the two alleles was reported (Porcellini et al., 2007). A possible reason for
this discrepancy is the type of cell lines used – Porcellini et al used cells derived from adult
sources while we used cells of embryonic origin. Additionally, in the study by Porcellini et al
Gateway™ gene recombination technology was used to transfer the cloned promoter into the
reporter vector. In this technique 102 bp sequences flank the DNA sequence of interest and
permit easy subcloning of the sequence into other vectors. Inspection of these sequences
revealed potential binding sites for SREBP, which is known to interact with DNA relatively
promiscuously. It is possible that the robust differences we observe in the basal and SREBP
regulated reporter activity may have been masked by the presence of these additional
sequences in the study by Porcellini et al.
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An intriguing finding of the present work is that, under in vitro conditions, the A allele was
significantly more responsive to SREBP-2 compared to the C allele. If this differential
responsiveness is preserved in vivo at both the protein and enzyme activity levels, it would be
anticipated that stimulation by SREBP would lead to a greater flux through the cholesterol
synthesis pathway in carriers of the minor allele. Given that cholesterol is only one of many
isoprenoids downstream of HMGCR activity, this polymorphism may have consequences on
other biological processes. In preliminary studies we were unable to demonstrate a difference
in lathosterol levels between the two genotypes (results not shown). In the current context it is
noteworthy that the major pathway for removal of cholesterol from the brain is sensitive to the
flux through the cholesterol synthesis pathway and that a decrease in this flux is associated
with profound learning difficulties in mice (Kotti et al., 2006).

We clearly observed lower cholesterol in the plasma of the AD cases than the controls,
despite the fact that these samples were not rigorously controlled for prandial status or drug
treatment. This is in general agreement with previous epidemiological reports which show
elevated mid-life cholesterol levels and decreased levels in later life in AD cases (Stewart et
al., 2007). Some studies have also indicated that there may be an association between low
plasma cholesterol and AD (Mielke et al., 2005), although these are not universal findings.
Given the relatively large numbers of samples involved (even taking into account some
missing data) it is unlikely that the observed difference is due to differences in prandial status
or dietary intake, and it is known that differences between fasting and non fasting cholesterol
are relatively small (Craig et al., 2000; Di Angelantonio et al., 2009). Despite this, it is
possible that over the long term, differences in dietary habits may contribute to the observed
changes. It is worth noting, however, that these are not isolated findings and a recent paper
from Soloman et al revealed a tendency towards lower cholesterol levels in AD patients
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(Solomon et al., 2009). Comparison of the cholesterol levels between APOE ε4 carriers and
non-carriers revealed that individuals carrying the ε4 allele (cases and controls together) had a
tendency towards higher levels of cholesterol than those without (P = 0.054), in line with
findings from previous studies (reviewed in (Hagberg et al., 2000; Ordovas and Mooser,
2002)).

We were unable to replicate the previous finding that the A allele is associated with AD
(Porcellini et al., 2007). It should be noted that although Porcellini et al reported an
association for their entire population, the effect appears to be due to an increased frequency
of the A allele in AD cases without an APOE ε4 allele. The above results may be confounded
by an under-representation of APOE ε4 carriers due to the established decrease in APOE ε4
allele frequencies from northern to southern Europe. In the present work we found an increase
in risk for AD in individuals carrying the combination of ε4 and an A allele, compared to ε4
negative A carriers. While we were unable to formally demonstrate an interaction between
these genes (P = 0.07) we consider this to be a biologically relevant interaction that warrants
further investigation (cf below). In support of our findings, a recent genome wide association
study, performed to identify new loci that influence lipid concentrations (Willer et al., 2008),
failed to identify the HMGCR gene as a potential modifier of cholesterol concentrations using
Affymetrix and Illumina arrays that each contained the polymorphism of interest (rs3761740).

The interpretation of the biochemical consequences of a potential interaction between
variations in the APOE and the HMGCR genes is difficult, particularly given our poor
understanding of the mechanisms underpinning brain cholesterol homeostasis. However, it
can be speculated that the decreased basal cholesterol synthesis would lead to a decreased
lipidation of APOE containing lipoproteins. In addition, the dependence of APOE secretion
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on prenylation is well established (Naidu et al., 2002), suggesting reduced flux through the
mevalonate pathway may have multiple effects on APOE secretion. A very recent study
reported that total brain APOE levels are influenced by the APOE genotype, with APOE4
associated with lowest levels (Riddell et al., 2008). The combination of the APOE ε4 and
HMGCR A alleles may thus influence the both the production and release of cholesterol from
astrocytes, which are believed to be the major site of both cholesterol and APOE synthesis in
the brain (Pfrieger, 2003). Ultimately this may influence the availability of cholesterol within
the central nervous system. Moreover, the low basal activity of the A allele of HMGCR may
contribute to a decreased cholesterol biosynthesis, a perceived cholesterol deficiency and an
activation of SREBP-2. Given the apparent sensitivity of the A allele to SREBP-2 mediated
regulation, in the presence of APOE 4 this may lead to a scenario where cholesterol is
produced but not secreted, leading to cholesterol based dysfunction of astroglial cells. It is
noteworthy that such astroglial activation occurs in Niemann Pick Disease Type-C, a
cholesterol storage disease that presents histologically with neurofibrillary tangles identical to
those in AD (Love et al., 1995). In support of potential interactions between APOE and
HMGCR, a recent study by Recuero et al (Recuero et al., 2009) found that there was a trend
towards a link between an a 3’ SNP in the HMGCR gene and APOE, in that the greatest
decrease in risk was present in APOE 4 carrier women.

This is the first study to show that the -911 C>A polymorphism in the promoter region of the
HMGCR gene has a functional role for the transcriptional activity. The SNP has not
previously been investigated for its effect on plasma cholesterol levels or on the risk for AD
in Swedish populations. Although we were unable to find differences in plasma cholesterol
levels between carriers of the different alleles or an association to AD, our results suggest that
the A allele of the HMGCR -911 C>A SNP may act together with the APOE 4 allele to
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increase the risk of AD in a manner which is independent of its effect on plasma cholesterol
levels. Further studies are required to confirm or refute this hypothesis.
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Materials and Methods

Cloning and analysis of the human HMGCR promoter

A DNA fragment corresponding to bp –1221 to +85 of the human HMGCR promoter and
containing the polymorphism of interest [rs3761740] (Figure 1) was amplified by PCR using
Phusion™ High-Fidelity DNA polymerase (Finnzyme Oy, Finland) using purified human
genomic DNA as a template and the primers HMGCR-F (5´–
TCCTTAATAAATTTCCACATACGATAG–3´) and HMGCR-R (5´–
CCTCACCTCCAGATCTCACTAGA–3´). Adenosine overhangs were added after the initial
PCR step using Dynazyme EXT and dATP (Finnzyme Oy, Finland). The PCR product was
purified and ligated into pCR2.1 plasmid according to standard techniques. After combined
SacΙ and XhoΙ digestion a 1306 bp DNA fragment was released and subsequently
directionally inserted into the pGL3 basic vector (Promega Biotech AB, Nacka, Stockholm) to
yield pGL3-HMG-C. To create the corresponding A containing vector pGL3-HMG-C was
mutated using site directed mutagenesis and the following primers: MutFoward – 5´–
CAGAAATGTGTGGTGGGGACATATTAGTGGTGACAGG–3´, MutReverse – 5´–
CCTGTCACCACTAATATGTCCCCACCACACATTTCTG–3´ (the mutated bases are
underlined). The resulting plasmid was designated pGL3-HMG-A. The integrity of all
constructs was verified by DNA sequencing with 2-fold coverage (Cybergene AB, Huddinge,
Sweden).

Human embryonic kidney cells (HEK 293; ATCC Catalog No. CRL-1573, American Type
Culture Collection, Manassas, USA) were cultured at 37°C in Dulbecco’s Modified Eagle
Medium with 10% (v/v) FBS and Penicillin/Streptomycin (100 IU mL-1/ 100 µg mL-1;
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Invitrogen) in an atmosphere of 5% CO2. Cells were expanded in 175 cm2 flasks and
subsequently seeded into 24-well plates. Cells at 80% confluence were transfected with the
pGL3-HMG reporter gene constructs and co-transfected with either the empty pGL3-basic
vector or an SREBP-2 expression plasmid (total DNA 0.3µg/well) with TfxTM20 Reagent
(Promega Biotech AB, Nacka, Stockholm) at a DNA:Tfx20 ratio of 1:3. One hour following
the transfection, cells were overlaid with complete medium. Forty hours after transfection
cells were lysed and assayed for luciferase activity according to the manufacturer’s protocol
using the Luciferase Reporter Gene Assay (Promega Corp USA) and a Wallac 1420 VictorTM
luminometer (Wallac Oy, Turku, Finland). The luciferase measurement was normalised to the
protein concentration in each well and is expressed as relative light units/mg total protein. Six
independent transfections were performed. Protein concentration determination was
performed using the Bradford technique (Bradford, 1976).

Investigation of the association of the HMGCR rs3761740 polymorphism with risk of
Alzheimer Disease

This study was performed on a case-control sample set that was frequency matched for age
and gender. 372 cases with LOAD were recruited from the Memory Clinic at Karolinska
University Hospital - Huddinge, Sweden. All cases were diagnosed with AD at the age of 67
years or older and the mean age of diagnosis was 79 years. The clinical diagnosis of AD was
based on NINCDS-ADRDA criteria (McKhann et al., 1984). The 348 controls were frequency
matched for age and gender and selected from an ongoing longitudinal study (The Swedish
Study on Aging and Care on Kungsholmen, SNACK (Lagergren et al., 2004)). All control
subjects met Mini Mental State Examination exclusion criteria for dementia (cut off
MMSE 28/30). The case sample set has been reported previously (Björk et al., 2007). All
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participating subjects, or a proxy, gave informed consent and the study was approved by the
local ethics committee.

DNA was extracted from peripheral blood samples obtained during the clinical investigation
of memory complaints (AD patients) or during the baseline examination in the SNACK study
or during first follow up examination (healthy controls). Samples were genotyped as
described above. Genotyping was performed blinded to case and control status which was
mixed on each 96-well plate.

Due to the nature of the available samples, total cholesterol was measured without a prior
standardized fasting period. Measurements of cholesterol levels in controls were done at the
baseline examination while the cholesterol measurement of AD patients was done during the
clinical investigation. In 29% of the cases and in less than 1% of the controls cholesterol
levels were unavailable.

Statistical analysis
Statistical analyses were performed using STATA 9.2 statistical software (StatCorp., 2006) or
SAS 9.1 (SAS Institute Inc., Cary, NC, USA). Measurements that did not adhere to the
Normal Distribution were normalized by logarithmic transformation before statistical
analysis. T-test and one-way analysis of variance was used to analyze group differences in
plasma biomarkers. All data are presented as mean ± standard deviation unless otherwise
indicated. Exact tests for Hardy Weinberg equilibrium (HWE) were performed on the
HMGCR genotypes for cases and controls separately.
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The relationship between the HMGCR -911 C>A SNP and the APOE ε4 allele and AD was
estimated by logistic regression and the results are presented as odds ratios (ORs) with
corresponding 95% CI. All regression models were adjusted for cholesterol levels, unless
otherwise stated. Two-way statistical interaction was examined between the HMGCR 911C>A SNP and the APOE ε4 allele by including the two independent variables and their
cross-product terms in the same regression model. To further evaluate the relation between
the APOE ε4 allele, the HMGCR -911C>A SNP and AD a categorical variable was created by
combining the genetic information that was included in a logistic regression model.
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Figure legends:

Figure 1. Promoter of the human HMGCR gene. The SNP at –911 is denoted by a white C on
a grey field. Known sterol response elements present in the human HMGCR promoter are
indicated.

Figure 2. Transfection of the human HMGCR reporter constructs into HEK293 cells. A) Cells
were transfected with either pGL3-HMGCR-A or pGL3-HMGCR-C respectively (n=6) using
TfxTM20 reagent. B) Cells were co-transfected with either empty pGL3-Basic of an expression
plasmid for SREBP-2. 40hr post transfection, cells were lysed and the lysates assayed for
luciferase activity. All values are expressed as means ± standard error of the mean.
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Table 1. Genotype distribution of the HMGCR rs3761740 polymorphism in healthy controls
and AD cases.
Total

Controls

Cases

HMGCR -911C>A, n (%)
CC

566 (0.79)

276 (0.80)

290 (0.79)

CA

140 (0.20)

67 (0.19)

73 (0.20)

AA

8 (0.01)

4 (0.01)

4 (0.01)

400 (0.56)

257(0.74)

143 (0.39)

313 (0.44)

90 (0.26)

223 (0.61)

APOE ε4
ε4, n (%)1
Non−ε4
ε4
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Table 2. OR and 95% confidence intervals (CI) for AD according to presence of the APOE ε4
allele and the HMGCR -911A allele.
OR# (95% CI)

APOE ε4

HMGCR A

Subjects AD Cases

No

No

288

86

1.0 (ref)

No

Yes

68

15

0.66 (0.35-1.24)

0.199

Yes

No

194

123

4.57 (3.06-6.81)

< 0.001

Yes

Yes

58

40

6.21 (3.30-11.68)

< 0.001

#

P value

ORs are adjusted for cholesterol levels.
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